Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vistagen Therapeutics, Inc.

NASDAQ: VTGN · Life Sciences · 8 alerts · CIK 1411685

Share price
$0.1843Close, Nov 16
Market cap
$8.51M
Shares outstanding
46.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vistagen Therapeutics, Inc. filings on SEC EDGAR ↗

7:31 AM ET 8-K
Clinical Trial Data

Vistagen Therapeutics Clinical Trial Data

Vistagen presented positive exploratory data at Psych Congress 2026 showing that its Phase 3 candidate fasedienol (PH94B) demonstrated statistically significant improvements in anxiety symptoms for patients with very severe social anxiety disorder. The findings, derived from post-hoc and prespecified subpopulation analyses of the PALISADE-4 and Phase 2a RDS trials, suggest that fasedienol may provide rapid-onset relief and that a second dose could further improve anticipatory anxiety.

4:23 PM ET 8-K
Clinical Trial Data

Vistagen Therapeutics Clinical Trial Data

Vistagen announced preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder. The data showed the nasal spray was well-tolerated over 12 months of as-needed use and demonstrated clinically relevant improvements in social anxiety symptoms on both clinician-administered and patient-reported scales. The company plans to meet with the FDA this quarter to discuss the regulatory path forward for a potential New Drug Application.

Term
12 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.